arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Propanc Biopharma, Inc.

PPCB
$1.20 ▼ -0.17 (-12.41%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
64 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bullish
auto_awesome

Analytical Summary

Propanc Biopharma, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $26.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -51.2%
FCF / Share $-0.05
Trailing P/E
Price / Book 2.7x
FCF Yield
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Aug 7, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-4.84M
↓ -1265.4%
FCF / Share Free cash flow per share
$-0.05
↑ +32.0%
Long-Term Debt Long-term obligations
$55.00K
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
46
Cash Quality
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 64 quarters